Global Tuberculosis (TB) Diagnostics Market 2017-2021
About Tuberculosis (TB) Diagnostics
TB is a contagious infection that usually attacks the lungs. It may also spread to other parts of the body such as the brain and the spine. TB commonly spreads through the air when an infected person coughs, sneezes, spits, laughs, or talks. Mycobacterium tuberculosis is responsible for the onset of the disease. In the 20th century, TB was a leading cause of death. However, today, most cases are cured with antibiotics, which is a time-consuming process. Medicines should be taken for at least six to nine months.
Technavio’s analysts forecast the global tuberculosis (TB) diagnostics market to grow at a CAGR of 3.56% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global tuberculosis (TB) diagnostics market for 2017-2021. To calculate the market size, the report considers the new installations, shipments, sales, volume, and value.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Tuberculosis (TB) Diagnostics Market 2017-2021
Technavio recognizes the following companies as the key players in the global tuberculosis (TB) diagnostics market: Abbott, BD, bioMérieux, F. Hoffmann-La Roche, and Thermo Fisher Scientific
Other Prominent Vendors in the market are: Akonni Biosystems, Ameritek USA, Autobio Diagnostics, Cepheid, EIKEN CHEMICAL, GeTein BioMedical, Hain Lifescience, Hologic, NanoEnTek, Ortho Clinical Diagnostics, QIAGEN, and Siemens Healthineers.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Expansion of healthcare infrastructure. Healthcare infrastructure has constantly been expanding across the world. Efforts have also been made to make diagnostic facilities available in rural areas. People are encouraged to visit clinics or healthcare facilities in the vicinity to diagnose and treat diseases. This could reduce the burden of large test volumes from large hospitals. It would also reduce the burden of healthcare expenses rural and semi-urban populations. This is because out of pocket expense would decrease.”
According to the report, one of the major drivers for this market is Increasing prevalence of TB. TB affects a significant proportion of the population each year. In 2015, it was one of the 10 major causes of death, ranking above acquired immunodeficiency syndrome (AIDS). However, TB can be cured through early diagnosis and treatment.
Further, the report states that one of the major factors hindering the growth of this market is Accessibility and cost constraints of advanced TB diagnostics. New and improved diagnostics can reform TB diagnostics. However, it is important to make them accessible in clinics when patients initially seek medical attention for TB. For instance, despite its various features, Xpert was not considered as a POC test. It requires controlled environmental temperatures and continuous power supply, which are not generally accessible in the primary healthcare centers of low‑income countries. It is indicated that the full advantage of enhanced diagnostic tests can only be felt if they are actualized as POC tests. Hence, new diagnostic tests must be designed for low‑income countries. The equipment, skills, and environmental controls in peripheral laboratories are often limited.
Abbott, BD, bioMérieux, F. Hoffmann-La Roche, Thermo Fisher Scientific, Akonni Biosystems, Ameritek USA, Autobio Diagnostics, Cepheid, EIKEN CHEMICAL, GeTein BioMedical, Hain Lifescience, Hologic, NanoEnTek, Ortho Clinical Diagnostics, QIAGEN, and Siemens Healthineers.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook